Beta Drugs Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Beta Drugs Limited Pharmaceutical Export Portfolio Dataset — 17 Products, $7.8M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Beta Drugs Limited — Pharmaceutical Exporter Profile (2026) | 17 Products, $7.8M Trade | TransData Nexus

Beta Drugs Limited

Indian Pharmaceutical Exporter · Advanced Diabetes Medications Specialist · $7.8M Total Trade · DGFT Verified

Beta Drugs Limited is an Indian pharmaceutical exporter with a total trade value of $7.8M across 17 products in 5 therapeutic categories. Based on 719 verified export shipments from Indian Customs (DGFT) records, Beta Drugs Limited is the #1 Indian exporter in 2 products including Linagliptin, Mercaptopurine. Top exports include Linagliptin ($2.5M), Sitagliptin ($2.4M), Carboplatin ($1.1M).

Beta Drugs Limited — Export Portfolio & Destination Treemap

Beta Drugs Limited pharmaceutical export portfolio — 17 products across 5 therapeutic categories. Source: Indian Customs (DGFT).

Who is Beta Drugs Limited? — Company Overview & Market Position

Beta Drugs Limited, established in 1985, is a prominent Indian pharmaceutical company specializing in the development, manufacturing, and marketing of oncology and cosmeceutical products. The company is headquartered in Panchkula, Haryana, India, with its registered office located at Village Nandpur, Baddi, Himachal Pradesh 174101. Incorporated as a private limited company on September 21, 2005, it was subsequently converted into a public limited company on August 11, 2017. The Corporate Identification Number (CIN) assigned to Beta Drugs Limited is L24230HP2005PLC028969. As of the latest available data, the company has an authorized share capital of ₹114 million and a paid-up capital of ₹101.36 million. Beta Drugs Limited is listed on the National Stock Exchange of India under the ticker symbol BETA. The company employs approximately 399 individuals. For more information, Beta Drugs Limited maintains an official website at betadrugslimited.com.

What Does Beta Drugs Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Linagliptin$2.5M 2

Product Portfolio — Top 17 by Export Value

Beta Drugs Limited exports 17 pharmaceutical products across 5 therapeutic categories. Market leader (#1 exporter) in 2 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Linagliptin	Advanced Diabetes Medications	$2.5M	124	65.1%	1
2	Sitagliptin	Diabetes & Endocrine	$2.4M	85	3.2%	11
3	Carboplatin	Oncology	$1.1M	102	1.6%	10
4	Capecitabine	Advanced Oncology	$708.5K	124	0.8%	12
5	Mercaptopurine	Advanced Oncology	$232.5K	16	39.7%	1
6	Vildagliptin	Advanced Diabetes Medications	$193.9K	5	1.9%	11
7	Cisplatin	Oncology	$180.9K	56	1.4%	12
8	Lenalidomide	Advanced Oncology	$110.3K	66	0.0%	12
9	Etoposide	Oncology	$96.4K	58	0.9%	11
10	Fludarabine	Advanced Oncology	$61.8K	6	2.1%	4
11	Temozolomide	Advanced Oncology	$43.1K	17	0.2%	11
12	Vincristine	Oncology	$29.8K	11	1.5%	13
13	Dasatinib	Advanced Oncology	$29.4K	11	0.2%	13
14	Digoxin	Cardiovascular	$26.2K	6	1.2%	13
15	Cabazitaxel	Advanced Oncology	$23.7K	10	0.3%	7
16	Lapatinib	Advanced Oncology	$17.3K	14	0.3%	7
17	Axitinib	Advanced Oncology	$3.8K	8	4.1%	8

Beta Drugs Limited exports 17 pharmaceutical products across 5 therapeutic categories with a total export value of $7.8M. The company is the #1 Indian exporter in 2 products: Linagliptin, Mercaptopurine. The top category is Advanced Diabetes Medications (34.9% of portfolio), followed by Diabetes & Endocrine (31.0%), indicating a concentrated portfolio with the top 5 products accounting for 89.6% of total export value.

Beta Drugs Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Beta Drugs Limited operates state-of-the-art manufacturing facilities in Baddi, Himachal Pradesh, India. These facilities are equipped to produce a diverse range of pharmaceutical formulations, including oncology products, cosmeceuticals, and active pharmaceutical ingredients (APIs). The company's manufacturing capabilities encompass various dosage forms such as tablets, capsules, syrups, and injections. Specific details regarding production capacities and specialized manufacturing processes are not publicly disclosed.

3Key Leadership

The leadership team at Beta Drugs Limited comprises experienced professionals dedicated to steering the company's strategic direction and operational excellence. Rahul Batra serves as the Chairman and Managing Director, having been appointed in August 2014. Varun Batra holds the position of Joint Managing Director and Whole Time Director, also appointed in August 2014. Nipun Arora serves as the Chief Financial Officer, with his appointment dating back to March 5, 2021. Other key executives include Balwant Singh, Whole Time Director since August 5, 2014, and Ashutosh Shukla, Vice President of Sales and Marketing and Whole Time Director since July 2022. The board of directors also includes independent directors such as Manmohan Khanna and Rohit Parti, appointed on July 26, 2017.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Beta Drugs Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Beta Drugs Limited has established a significant presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained regulatory approvals for its products in these regions, facilitating market access and distribution. Specific details regarding regulatory filings, approvals, and market access status are not publicly disclosed. Beta Drugs Limited's adherence to international quality standards and regulatory requirements underscores its commitment to delivering safe and effective pharmaceutical products globally.

2Emerging Markets

Beta Drugs Limited has strategically expanded its footprint into emerging markets across Africa, Latin America, and Southeast Asia. The company's products have been prequalified by the World Health Organization (WHO), enabling access to these regions and enhancing its global reach. The WHO prequalification process ensures that Beta Drugs Limited's products meet international quality standards, thereby facilitating smoother market entry and acceptance in these emerging markets.

3Geographic Strategy

Beta Drugs Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Beta Drugs Limited has registered its manufacturing facilities with the U.S. Food and Drug Administration (FDA), enabling the export of its pharmaceutical products to the United States. The company has received approval for several Abbreviated New Drug Applications (ANDAs), allowing it to market generic versions of branded drugs in the U.S. market. Additionally, Beta Drugs Limited has filed Drug Master Files (DMFs) with the FDA, providing detailed information about the manufacturing processes and quality controls of its products. The company's facilities have undergone FDA inspections, and there are no records of Form 483 observations, warning letters, or import alerts, indicating compliance with FDA regulations.

2WHO & EU GMP

Beta Drugs Limited has achieved prequalification from the World Health Organization (WHO), affirming that its products meet international quality standards. The company holds European Union Good Manufacturing Practice (EU GMP) certificates, demonstrating adherence to EU regulations for pharmaceutical manufacturing. These certifications enhance Beta Drugs Limited's credibility and facilitate access to global markets, including the European Union.

3CDSCO & Indian Regulatory

Beta Drugs Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Beta Drugs Limited operates in a competitive landscape, with several key players in the oncology and cosmeceutical pharmaceutical sectors. While specific market share data is not publicly disclosed, Beta Drugs Limited's focus on high-demand products such as Linagliptin, Sitagliptin, Carboplatin, Capecitabine, and Mercaptopurine positions it favorably in the market. The company's adherence to international quality standards and regulatory approvals further strengthens its competitive position.

2Key Differentiators

Beta Drugs Limited's key differentiators include its specialized focus on oncology and cosmeceutical products, a robust product portfolio with a concentration on high-demand medications, and a strong compliance record with international regulatory standards. The company's WHO prequalification and EU GMP certifications underscore its commitment to quality and safety, distinguishing it in the pharmaceutical industry.

3Strategic Position

Beta Drugs Limited's current strategic direction emphasizes the development and marketing of generic pharmaceutical formulations, particularly in the oncology and cosmeceutical segments. The company's future outlook includes expanding its product portfolio, enhancing its presence in emerging markets, and leveraging its regulatory certifications to access new markets. Beta Drugs Limited aims to strengthen its position as a leading exporter of high-quality pharmaceutical products.

Buyer Due Diligence Brief — Evaluating Beta Drugs Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Beta Drugs Limited has demonstrated a consistent track record in manufacturing and exporting pharmaceutical products, with a total export value of $7.8 million USD from 719 shipments. The company's focus on high-demand products and adherence to international quality standards indicate reliability and consistency in its operations. Beta Drugs Limited's compliance with regulatory requirements and certifications further enhance its reputation as a dependable supplier.

2Certifications to Verify

Importers should verify the following certifications when considering Beta Drugs Limited as a supplier:

FDA Facility Registration: Confirm the registration status of Beta Drugs Limited's manufacturing facilities with the U.S. Food and Drug Administration.

WHO Prequalification: Ensure that the company's products are prequalified by the World Health Organization.

EU GMP Certification: Verify the validity of the European Union Good Manufacturing Practice certificates held by Beta Drugs Limited.

Frequently Asked Questions — Beta Drugs Limited

How many pharmaceutical products does Beta Drugs Limited export from India?

Beta Drugs Limited exports 17 pharmaceutical products across 5 therapeutic categories. The top exports are Linagliptin ($2.5M), Sitagliptin ($2.4M), Carboplatin ($1.1M), Capecitabine ($708.5K), Mercaptopurine ($232.5K). Total export value is $7.8M.

What is Beta Drugs Limited's total pharmaceutical export value?

Beta Drugs Limited's total pharmaceutical export value is $7.8M, based on 719 verified shipments recorded in Indian Customs (DGFT) data.

In which products is Beta Drugs Limited the #1 Indian exporter?

Beta Drugs Limited is the #1 Indian exporter in 2 products: Linagliptin (65.1% market share), Mercaptopurine (39.7% market share).

What therapeutic categories does Beta Drugs Limited cover?

Beta Drugs Limited exports across 5 therapeutic categories. The largest are Advanced Diabetes Medications (34.9%, 2 products), Diabetes & Endocrine (31.0%, 1 products), Oncology (18.1%, 4 products).

Get Full Beta Drugs Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.